Olaparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Olaparib (coding:ncit:C71721)

RxNorm: olaparib (coding:rxcui:1597582, coding:omop:45892579)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (4) BRCA1 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (4) BRCA1 pathogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (4) BRCA2 oncogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (4) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (4) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (4) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (4) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (4) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (4) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (4) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (4) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (4) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (2) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA1 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (2) HRD Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (2) HRD High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (1) FDA (2) HRD Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (2) FDA (4) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (2) FDA (4) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (1) FDA (2) BRCA1 pathogenic variants Pancreatic Adenocarcinoma Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants Pancreatic Adenocarcinoma Olaparib
EMA (1) FDA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) ATM pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) ATM oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) BARD1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) BARD1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) BRIP1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) BRIP1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) CDK12 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) CDK12 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) CHEK1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) CHEK1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) CHEK2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) CHEK2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) FANCL pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) FANCL oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) PALB2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) PALB2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) RAD51B pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) RAD51C pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) RAD51C oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) RAD51D pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) RAD51D oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) RAD54L pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) RAD54L oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
EMA (1) pMMR Endometrial Carcinoma Carboplatin, Durvalumab, Olaparib, Paclitaxel
EMA (1) pMMR Endometrial Carcinoma Durvalumab, Olaparib